RP-HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF EPROSARTAN MESYLATE IN PHARMACEUTICAL PREPARATIONS

Authors

  • Suresh Rewar Department of pharmaceutics, Arya College of Pharmacy, Jaipur, Rajasthan, India
  • A K Sharma Department of pharmacology, Arya College of Pharmacy, Jaipur, Rajasthan, India
  • B K Bansal Department of pharmaceutics, Arya College of Pharmacy, Jaipur, Rajasthan, India
  • C J Singh Department of pharmacology, Arya College of Pharmacy, Jaipur, Rajasthan, India

Keywords:

Eprosartan Mesylate, HPLC Determination.

Abstract

Objective: A simple, specific, accurate and precise Rp-high-performance liquid chromatography method was developed and validated for determination of Eprosartan Mesylate in pharmaceutical preparations.

Materials and Methods: The method showed a linear response for concentrations in the range of 2-12 μg/mL using Methanol: Acetonitrile: Buffer solution (Dissolve

0.02 M potassium di-hydrogen orthophosphate in water. Adjust pH of solution to 6.85 with orthophosphoric acid) in the ratio (45:45:10) as the mobile phase with detection at 233 nm and a flow rate of 1 mL/min and retention time 7.1 min. The value of correlation coefficient, slope and i ntercept were, 0.9998, 1661.8 and 114.82, respectively. The method was validated as per ICH guidelines for precision, recovery, ruggedness and robustness. The specificity of the method was investigated under different stress conditions including acidic, basic, photochemical and thermal as recommended by ICH guidelines.

Conclusions: The method was validated and successfully used for determination of the drugs in tablets.

Downloads

Download data is not yet available.

References

Blankestijn PJ, Rupp H. Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker. Cardiovascular & Hematological Agents in Medicinal Chemistry 2008; 6: 253-257.

William H. Frishman, Angela Cheng-Lai, James Nawarskas, the Current Cardiovascular Drugs. 2007. p.53.

B. Pitt, M.A. Konstam, Overview of angiotensin II- receptor antagonists, Am. J. Cardiol. 82 (1998) 47S– 48S.

Ruilope L, Jäger B.: Eprosartan for the treatment of hypertension, Expert Opin Pharmacother. (2003) Jan; 4(1):107-14.

Martin DE, Tompson D, Boike SC, et al. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. Br J Clin Pharmacol. (1997) 43:661.

McInnes GT.: Angiotensin II antagonists in systolic blood pressure control, Hosp Med. 2001 Dec; 62(12):773-7.

McClellan KJ, Balfour JA: Eprosartan. Drugs 1998; 55:713–718.

Conter HS, McKay DW, Reiz RJ. Eprosartan Mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting. Can J Cardiol. 2004 Oct; 20 Suppl C: 6C-10C.

M Kamila, N Mondal & L K Ghosh. Spectrophotometric determination of Eprosartan Mesylate in raw material and experimental tablets. Indian Journal of Chemical Technology, 2008, 15,194-196.

Carstensen J T and Rhodes C T, Drug Stability; 2nd Edn., Marcel Dekker, New York, 2008, 358.

Published

2015-05-15

How to Cite

Rewar, S. ., Sharma , A. K., Bansal, B. K., & Singh, . C. J. (2015). RP-HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF EPROSARTAN MESYLATE IN PHARMACEUTICAL PREPARATIONS. International Journal of Research and Development in Pharmacy & Life Sciences, 4(3), 1559-1568. Retrieved from https://ijrdpl.com/index.php/ijrdpl/article/view/474

Issue

Vol. 4 No. 3 (2015): Volume 4 Issue 3, April - May (2015)

Section

Research
Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.